These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20174751)

  • 1. Facts and artefacts of coagulation assays for factor Xa inhibitors.
    Haas S
    Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.
    Samama MM; Amiral J; Guinet C; Perzborn E; Depasse F
    Thromb Haemost; 2010 Nov; 104(5):1078-9. PubMed ID: 20806114
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
    Tichelaar V; de Jong H; Nijland H; Kluin-Nelemans H; Meijer K; Mulder A
    Thromb Haemost; 2011 Nov; 106(5):990-2. PubMed ID: 21901233
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.
    Gerotziafas GT; Baccouche H; Sassi M; Galea V; Chaari M; Hatmi M; Samama MM; Elalamy I
    Thromb Res; 2012 Jan; 129(1):101-3. PubMed ID: 22000405
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.
    Tripodi A; Chantarangkul V; Guinet C; Samama MM
    J Thromb Haemost; 2011 Jan; 9(1):226-8. PubMed ID: 20942848
    [No Abstract]   [Full Text] [Related]  

  • 9. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
    Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
    J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlating prothrombin time with plasma rivaroxaban level.
    Rodgers R; Bagot CN; Lawrence C; Hickman G; McGurk M; Tait RC
    Br J Haematol; 2013 Dec; 163(5):685-7. PubMed ID: 24219334
    [No Abstract]   [Full Text] [Related]  

  • 13. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin.
    Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C
    Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
    Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report.
    Than H; Loh JB; Sum CL; Ng HJ
    J Clin Pathol; 2015 Apr; 68(4):318-9. PubMed ID: 25688138
    [No Abstract]   [Full Text] [Related]  

  • 16. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
    Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
    Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
    Siriez R; Evrard J; Dogné JM; Pochet L; Gheldof D; Chatelain B; Mullier F; Douxfils J
    Thromb Haemost; 2018 Jul; 118(7):1203-1214. PubMed ID: 29890519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM
    Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study.
    Exner T; Ellwood L; Rubie J; Barancewicz A
    Thromb Haemost; 2013 Apr; 109(4):762-5. PubMed ID: 23364321
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring the new antithrombotic drugs.
    Walenga JM; Hoppensteadt DA
    Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.